A5071915018- Dementia and Cognitive Impairment Research
- Alzheimer's disease research and treatments
- Functional Brain Connectivity Studies
- Neurological Disease Mechanisms and Treatments
- Neuroinflammation and Neurodegeneration Mechanisms
- Alcohol Consumption and Health Effects
- Cancer-related cognitive impairment studies
- Tryptophan and brain disorders
- Advanced Neuroimaging Techniques and Applications
- Memory and Neural Mechanisms
- Brain Tumor Detection and Classification
- Substance Abuse Treatment and Outcomes
- Health Systems, Economic Evaluations, Quality of Life
- Geological and Geochemical Analysis
- Cognitive Functions and Memory
- Healthcare professionals’ stress and burnout
- Older Adults Driving Studies
- Health and Well-being Studies
- Innovations in Medical Education
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Geochemistry and Geologic Mapping
- Diet and metabolism studies
- Eicosanoids and Hypertension Pharmacology
- Medical Education and Admissions
- earthquake and tectonic studies
Washington University in St. Louis
2024-2025
Albert Einstein College of Medicine
2021-2024
Brigham and Women's Hospital
2022
Harvard University
2022
Massachusetts General Hospital
2022
Yeshiva University
2022
Montefiore Medical Center
2022
University of Pennsylvania
2022
Courant Institute of Mathematical Sciences
2009
New York University
2009
Abstract INTRODUCTION Blood tests have the potential to improve accuracy of Alzheimer's disease (AD) clinical diagnosis, which will enable greater access AD‐specific treatments. This study compared leading commercial blood for amyloid pathology and other AD‐related outcomes. METHODS Plasma samples from Disease Neuroimaging Initiative were assayed with AD C2N Diagnostics, Fujirebio ALZPath, Janssen, Roche Quanterix. Outcomes measures positron emission tomography (PET), tau PET, cortical...
Introduction: Blood tests have the potential to improve accuracy of Alzheimer disease (AD) clinical diagnosis, which will enable greater access AD-specific treatments. This study compared leading commercial blood for amyloid pathology and other AD-related outcomes. Methods: Plasma samples from Alzheimers Disease Neuroimaging Initiative were assayed with AD C2N Diagnostics, Fujirebio ALZPath, Janssen, Roche Quanterix. Outcomes measures positron emission tomography (PET), tau PET, cortical...
Among the participants of Alzheimer disease (AD) treatment trials, 40% do not show cognitive decline over 80 weeks follow-up. Identifying and excluding these individuals can increase power to detect effects. We aimed develop machine learning-based predictive models identify persons unlikely on placebo weeks. used data from arm EXPEDITION3 AD clinical trial a subpopulation Alzheimer's Disease Neuroimaging Initiative (ADNI). Participants in were patients with mild dementia biomarker evidence...
Background: Blood-based biomarkers (BBMs) are of growing interest in the field Alzheimer’s disease (AD) and related dementias. Objective: This study aimed to assess ability plasma 1) predict progression from mild cognitive impairment (MCI) dementia 2) improve predictive magnetic resonance imaging (MRI) cerebrospinal fluid (CSF) measures when combined. Methods: We used data Disease Neuroimaging Initiative. Machine learning models were trained using participants who remained cognitively stable...
Increasing evidence indicates that a subset of cognitively normal individuals has subtle cognitive impairment at baseline. We sought to identify them using the Stages Objective Memory Impairment (SOMI) system. Symptomatic was operationalized by Clinical Dementia Rating (CDR) ≥0.5. hypothesized incident would be higher for participants with retrieval (SOMI-1), still those moderate (SOMI-2), and highest storage (SOMI-3/4) after adjusting demographics
To develop and test the performance of Positive Aβ Risk Score (PARS) for prediction β-amyloid (Aβ) positivity in cognitively unimpaired individuals use clinical research. Detecting is essential identifying at-risk who are candidates early intervention with amyloid targeted treatments.We used data from 4,134 normal Anti-Amyloid Treatment Asymptomatic Alzheimer's (A4) Study. The sample was divided into training sets. A modified version AutoScore, a machine learning-based software tool, to...
Alcohol use disorders have been categorized as a 'strongly modifiable' risk factor for dementia. To investigate the cross-sectional association between alcohol consumption and cognition in older adults if it is different across sexes or depends on amyloid-β (Aβ) accumulation brain. Cognitively unimpaired (N = 4387) with objective subjective cognitive assessments amyloid positron emission tomography (PET) imaging were classified into four categories based their average daily use....
Cognitive decline follows pathological changes including neurodegeneration on the Alzheimer's disease continuum. However, it is unclear which cognitive domains first become affected by in amyloid-positive individuals and if sex or apolipoprotein (APOE) ε4 status differences affect this relationship.Data from 1233 cognitively unimpaired, 65 to 85 years of age were studied assess effect hippocampal volume (HV) cognition evaluate due APOE status.Lower HV was linked with worse performance...
Medical students (MS) are at higher risk for depression than their peers. Incoming U.S. MS completed a survey that included the validated RS-14, which measures resilience and its two subcomponents: self-assuredness drive. Surveys were administered before classes started in 2019 (pre-pandemic-cohort; n = 178) 2020 (pandemic-cohort; 181). Resiliency, self-assuredness, drive not different between cohorts. Demographic subgroup analyses revealed underrepresented medicine (URiM)...
Understanding the heterogeneity of brain structure in individuals with Motoric Cognitive Risk Syndrome (MCR) may improve current risk assessments dementia.
Abstract Background Alzheimer’s disease (AD) is a heterogeneous with different clinical phenotypes and pathophysiological subtypes. Identifying cognitive/functional subtypes in AD could elucidate the diverse progression patterns. The Cognitive Function Index (CFI), 15‐item questionnaire completed by participants study partners, captures aspects of cognitive functional decline. We investigated participant heterogeneity using CFI compared differences between based on or partner reports....
Abstract Background Blood tests that accurately determine the presence of amyloid pathology are critically needed. Compared to PET and CSF tests, blood less expensive, invasive, more accessible, highly scalable. The Foundation for National Institutes Health (FNIH) Biomarkers Consortium evaluated accuracies leading AD in classifying status. Method Assays from C 2 N Diagnostics (Aβ42, Aβ40, p‐tau217, p‐tau217 ratio [phosphorylated non‐phosphorylated tau at position 217]), Fujirebio p‐tau217),...
Abstract Background Alzheimer’s disease (AD) is a complex heterogeneous neurodegenerative disease. Unsupervised clustering techniques have been used to identify subtypes, but such approaches are limited since subtypes may not directly be related progression. Herein, we implement novel supervised approach that aims MRI‐derived likely experience incident cognitive impairment (ICI). Methods We data from 822 cognitively normal individuals (68.4 ± 9.5 years old) with Clinical Dementia Rating®...
Abstract Background The Motoric Cognitive Risk Syndrome (MCR) is a predementia stage characterized by slow gait speed and subjective cognitive complaints. Defining the heterogeneity of brain volumetrics in individuals with MCR will improve current dementia risk assessments. Method We used data from 6 cohorts consortium (N=2,007). K‐means clustering algorithm guided volumetric MRI to identify distinct subgroups participants. compared differences cortical subcortical volumes, comorbidities,...
Abstract Background Alzheimer's disease exhibits heterogeneity through varied phenotypic and pathological manifestations. Here, we aimed to investigate the potential of semi‐supervised pattern classification applied volumetric MRI data in identifying relatively homogeneous subgroups individuals exhibiting cognitive decline (CD) throughout study period. Method We used from placebo arm trial Solanezumab for mild dementia due AD (EXPEDITION‐3 trial). Participants were classified as showing CD...
Abstract Background The Motoric Cognitive Risk Syndrome (MCR) is a predementia stage characterized by slow gait speed and subjective cognitive complaints. Defining the heterogeneity of brain volumetrics in individuals with MCR will improve current dementia risk assessments. Method We used data from 6 cohorts consortium (N=2,007). K‐means clustering algorithm guided volumetric MRI to identify distinct subgroups participants. compared differences cortical subcortical volumes, comorbidities,...
Abstract Background Alzheimer’s disease (AD) is a heterogeneous with different clinical phenotypes and pathophysiological subtypes. Identifying cognitive/functional subtypes in AD could elucidate the diverse progression patterns. The Cognitive Function Index (CFI), 15‐item questionnaire completed by participants study partners, captures aspects of cognitive functional decline. We investigated participant heterogeneity using CFI compared differences between based on or partner reports....
Abstract Background Of persons randomized to the placebo arm of Alzheimer’s Disease (AD) treatment trials, 40% do not show cognitive decline over 80 weeks follow-up. Identifying and excluding these individuals from both arms clinical trials (RCTs) AD has potential increase power detect effects. Objectives We aimed develop machine learning-based predictive models identify unlikely on weeks. Method used data 1072 patients with mild dementia biomarker evidence amyloid burden EXPEDITION3 trial....
Abstract Plasma biomarkers for Alzheimer’s disease (AD) are increasingly being used to assist in making an etiological diagnosis cognitively impaired (CI) individuals or identify unimpaired (CU) with AD pathology who may be eligible prevention trials. However, a better understanding of the timing plasma biomarker changes is needed optimize their use clinical and research settings. The aim this study was evaluate change key (Aβ42/Aβ40, p-tau217, p-tau181, GFAP NfL) from six different...
A growing body of evidence suggests that neuroinflammation contributes actively to pathophysiology Alzheimer's disease (AD) and promotes AD progression. The predictive value neuroinflammatory biomarkers for disease-staging or estimating progression is not well understood. In this study, we investigate the diagnostic prognostic utility inflammatory in combination with conventional biomarkers.